The most asked question in cosmetics sourcing is simple: how many units do I have to buy? The answer depends entirely on what you're making. Here are typical industry ranges across the most common product types.

Lip products (balms, glosses, lipsticks). MOQ ranges: 500–2,000 units for stock-formula private label. Lipstick in bullet format usually requires 1,000–3,000 units because tooling costs for the bullet mold must be amortized. Lip balm in twist-up or pot format starts as low as 500 units at domestic labs. Gloss tubes start at 1,000 units due to component minimums.

Foundation and complexion products. Liquid foundations: 1,000–5,000 units. The spread is wide because pump and airless-bottle tooling adds cost at the low end. Pressed powder: 500–2,000 units. BB and CC creams: 1,000–3,000 units. These are formula-sensitive categories — any SPF claim triggers OTC drug status and a different compliance path.

Eyeshadow palettes. Single-shade pans: 500–1,500 units. Multi-pan palettes: 500–1,000 palette units, but the total unit count per shade runs higher when you factor in each pan fill. Korean OEM labs are the dominant sourcing option here for sub-5,000 unit budgets. Domestic labs typically decline eyeshadow palette runs under 3,000 units.

Serums and treatments. 1,000–3,000 units. Airless pump packaging drives MOQs up. Dropper-bottle serums start lower (500–1,000 units) because the packaging is off-the-shelf. Any serum with an active retinol, niacinamide, or AHA concentration claim needs substantiation documentation regardless of MOQ.

Body care (lotions, body butter, scrubs). 500–2,000 units. One of the friendlier categories for first-run private label because packaging is often standard jars and tubes. Body scrubs can start at 300–500 units at smaller domestic labs.

None of these ranges are fixed across all facilities. Korean OEM labs often quote 20–40 percent lower MOQs than domestic US labs on the same format. Chinese OEM labs often quote the lowest unit costs but require higher overall quantities (3,000+ units) to make the economics work once freight and customs are included.

The sourcing region decision for cosmetics is more nuanced than supplements because regulatory destination, formulation complexity, and packaging sourcing all interact.

Domestic US manufacturing wins when: Your brand is US-market-only for now. Your product is OTC drug-adjacent (SPF, acne, anti-dandruff) and you need a facility that already operates inside FDA drug cGMP framework. Your lead time is constrained — a retail buyer meeting in 10 weeks means domestic. Your brand story includes "made in USA" — this claim has FTC requirements and domestic manufacturing is the only clean path to it.

Korean OEM wins when: Your formula is a complex skincare product — peptides, ferment extracts, layered texture systems. You're launching with sub-1,000-unit runs and need a facility that won't penalize you on MOQ. Your brand positioning is K-beauty adjacent or premium skincare. You have 10–14 weeks of lead time available.

Chinese OEM wins when: You're at scale (5,000+ units per SKU) and per-unit cost is the primary driver. Your category is color cosmetics at mass-market price points. You've already validated the formula on smaller runs and are moving to a production-scale engagement. You have robust quality control infrastructure to manage incoming goods.

EU-based labs (Italy, France) win when: Your primary market is the EU and you want a facility already operating under EU Cosmetics Regulation 1223/2009. Prestige skincare, sun care, and professional-grade formulations are the strongest categories here. Expect 10–18 weeks and higher minimum costs.

A common path we see: launch on a Korean OEM stock formula to validate demand, then commission a domestic custom formulation for v2 once you know which SKUs are pulling. The Korean run funds the domestic development.

Lead times in cosmetics have two main drivers: whether you're using a stock formula or custom formulation, and where the facility is located. Here's a realistic breakdown.

Stock-formula private label, domestic US: 4–8 weeks. This assumes the formula is pre-validated, packaging is off-the-shelf, and the label artwork is submitted on time. Label artwork delays are the single most common reason a 4-week run becomes a 7-week run. Have your Pantone refs, INCI list, and legal disclaimers locked before you submit art.

Stock-formula private label, Korean OEM: 8–12 weeks. Add 3–4 weeks for ocean freight plus 1–2 weeks for customs clearance. Air freight compresses this to 10–12 weeks total. Most Korean OEM labs will offer an air-freight option for an upcharge — worth it for a launch-window-sensitive first run.

Custom formulation, domestic US: 12–20 weeks. Formula development: 4–6 weeks. Stability testing (accelerated): 3–4 months at minimum (but you can stage production after accelerated completion, not full 24-month shelf-life study). Total cycle from brief to goods in warehouse: 12–20 weeks depending on complexity.

Custom formulation, Korean OEM: 14–22 weeks. Development time is similar, but ocean freight adds 3–4 weeks at the back end. Labs in Incheon and Gyeonggi-do typically have faster formulation iteration cycles than domestic US because they maintain larger in-house active libraries.

The variable nobody quotes: component lead times. Specialty packaging — unique dropper tops, airless pumps, custom palette structures — often has its own 6–10 week lead time that runs in parallel with formulation. Miss the component window and your formula is ready but you're waiting on bottles. Order packaging components early.

Cosmetics compliance changed significantly in 2022 and 2023. Here is what applies now for brands selling in the US and EU.

FDA MoCRA (Modernization of Cosmetics Regulation Act of 2022). All cosmetic manufacturers and distributors with more than $1M in annual revenue must register their facilities with the FDA. Products must be listed. Serious adverse event reporting is mandatory. Facility records must be made available to FDA on request. MoCRA does not require pre-market approval — cosmetics remain self-affirmed safe — but it significantly increases the documentation burden. Your manufacturer should be able to confirm MoCRA registration and provide the registration number. Contract manufacturing agreements should specify which party owns MoCRA obligations.

cGMP for cosmetics. There is no FDA-mandatory cGMP standard for cosmetics (unlike supplements under 21 CFR Part 111). The international standard is ISO 22716:2007 — Good Manufacturing Practices for Cosmetics. ISO 22716 certification is third-party and requires a facility audit. Major retailers (Sephora, Ulta, Target) increasingly require ISO 22716 or equivalent from their suppliers. If your go-to-market path includes retail, check retailer requirements before finalizing your manufacturer.

OTC drug classification. If your cosmetic claims SPF protection, treats acne, controls dandruff, or makes any claim that modifies body function, it may be regulated as an OTC drug under FDA. OTC drugs require compliance with an applicable OTC monograph or an approved New Drug Application (NDA). Your manufacturer must hold drug GMP certification (21 CFR Parts 210/211) to produce OTC drugs — not just cosmetic GMP. This is not a gray area. Sunscreens labeled with SPF values are OTC drugs. Period.

EU CPNP (Cosmetic Products Notification Portal). Every cosmetic product placed on the EU market must be notified in the CPNP before going on sale. You need a Responsible Person (RP) established in the EU — a legal entity that takes regulatory responsibility for the product. You need a Product Information File (PIF) including a safety assessment by a qualified person. Ingredient restrictions under EU Cosmetics Regulation 1223/2009 are stricter than US rules — formaldehyde releasers, certain parabens, and hundreds of other ingredients are restricted or prohibited in the EU that are legal in the US. Verify ingredient compliance against the EU annexes before commissioning a formula intended for EU sale.

Internal link: see the Private Label service page for how PLS handles compliance documentation in our sourcing engagements.

Use this framework to route your sourcing brief before you spend time on quotes. Answer each question in order — the first "yes" is usually your answer.

Is your product OTC drug-adjacent (SPF, acne, anti-dandruff)? If yes → domestic US only. Your manufacturer needs FDA drug GMP. Korean and Chinese OEM labs rarely hold US drug GMP certification. Stop here.

Is your first-run MOQ under 1,000 units? If yes → Korean OEM is your first call. Korean labs routinely run 300–500 unit minimums on stock formulas. Domestic US labs at under 1,000 units are few and often require premium pricing to cover scheduling.

Is "made in USA" part of your brand story or retail requirement? If yes → domestic US only. The FTC requires that "made in USA" claims be substantiated — substantial transformation in the US, with all or virtually all components of US origin. A Korean formula assembled in a US lab does not qualify.

Is your formula a complex skincare system (layered actives, ferment extracts, K-beauty texture engineering)? If yes → Korean OEM. The active libraries and formulation expertise in Korean labs, particularly in Gyeonggi-do province, are unmatched for complex skincare at accessible price points.

Are you at 5,000+ units per SKU and cost is the primary driver? If yes → Chinese OEM. At volume, Chinese OEM per-unit costs for color cosmetics and basic skincare formats typically run 25–40 percent below Korean OEM and 40–60 percent below domestic US. Quality tier varies widely — demand ISO 22716 certification and conduct pre-production audits.

Is your primary market the EU? If yes → EU-based lab (Italy, France, Spain) or a Korean OEM with EU regulatory experience. They will already hold Responsible Person relationships and PIF-management infrastructure.

If none of the above criteria triggers a clear answer, default to domestic US for a first run. Regulatory simplicity and shorter lead times reduce first-run risk. See also: how to find a private label manufacturer.

The vetting process for cosmetics manufacturers is different from supplements. Here is a specific checklist for cosmetics.

ISO 22716 certification. This is the international cosmetic GMP standard. Ask for the certificate number, then verify it against the issuing body (Bureau Veritas, SGS, NSF, or equivalent). ISO 22716 certificates expire every 3 years — an expired certificate is the same as none. Some labs claim ISO 22716 compliance without certification. Know the difference.

MoCRA registration (for US-bound goods). The FDA's facility registration database is public. Ask for the facility registration number and verify it. If the lab is overseas but shipping to the US, the importer of record (often you) may have registration obligations — clarify in the manufacturing agreement.

In-house stability lab. Accelerated stability testing (40°C/75% RH, 3 months minimum) should be run on every new formula before production. Ask whether this is done in-house or outsourced. In-house is faster and cheaper — outsourced adds 2–4 weeks and cost.

Ingredient sourcing transparency. Ask for the full INCI name list and the country of origin for key actives. This matters for EU compliance (prohibited ingredients) and for "clean beauty" claims. If the lab can't give you country-of-origin on actives, they can't support a compliant PIF for EU sale.

OTC drug flag protocol. Does the lab proactively notify you when a formula or claim triggers OTC drug status? Strong labs do this automatically. Weak labs let you put SPF on a label without flagging the regulatory implication. This is a due-diligence requirement, not a nice-to-have.

Packaging compatibility testing. Ask whether the lab tests formula-packaging compatibility as part of standard stability. Some actives (vitamin C, retinol, acids) interact with certain packaging materials. Compatibility failures show up as color change, separation, or leakage — after the production run ships.

See also: formula development services and packaging design for how these steps integrate into a sourcing engagement.